Results 181 to 190 of about 8,293,788 (383)

Understanding the tumor immune microenvironment (TIME) for effective therapy

Nature Network Boston, 2018
M. Binnewies, Edward W. Roberts, K. Kersten, Vincent Chan, Douglas Fearon, M. Merad, L. Coussens, D. Gabrilovich, S. Ostrand-Rosenberg, S. Ostrand-Rosenberg, C. Hedrick, R. Vonderheide, M. Pittet, R. Jain, W. Zou, T. Howcroft, E. Woodhouse, R. Weinberg, M. Krummel   +18 more
semanticscholar   +1 more source

The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl‐xL or Mcl‐1 in ovarian cancer

Molecular Oncology, EarlyView.
The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine, Sterenn Guillemot, Louis‐Bastien Weiswald, Romane Florent, Edwige Abeilard, Florence Giffard, Emilie Brotin, Mélanie Briand, Enora Dolivet, Laurent Poulain, Marie Villedieu   +10 more
wiley   +1 more source

Clinicopathological observation and prognostic factors of invasive breast cancer with medullary in Xinjiang

BMC Medical Informatics and Decision Making
Background Invasive breast cancer (BC) with medullary is a special type of BC, accounting for 3 ~ 6% of invasive BC. To investigate clinicopathological characteristics concerning invasive BC with medullary in Xinjiang area and analyze the prognostic ...
Yan Li, Xiaoping Ma, Zhenhui Zhao, Li Li, Chunyan Gao, Dan Liu, Bingyu Li, Bing Zhao   +7 more
doaj   +1 more source

The histological effects of nitrogen mustards on human tumors and tissues [PDF]

, 1948
Sophie Spitz
openalex   +1 more source

The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS)

IEEE Transactions on Medical Imaging, 2015
Bjoern H Menze, A. Jakab, S. Bauer, Jayashree Kalpathy-Cramer, K. Farahani, J. Kirby, Y. Burren, N. Porz, J. Slotboom, R. Wiest, L. Lanczi, E. Gerstner, M. Weber, T. Arbel, B. Avants, N. Ayache, Patricia Buendia, D. Collins, Nicolas Cordier, Jason J. Corso, A. Criminisi, T. Das, H. Delingette, Çağatay Demiralp, C. Durst, M. Dojat, Senan Doyle, Joana Festa, F. Forbes, Ezequiel Geremia, B. Glocker, P. Golland, Xiaotao Guo, A. Hamamci, K. Iftekharuddin, R. Jena, N. John, E. Konukoglu, D. Lashkari, J. Mariz, Raphael Meier, Sérgio Pereira, Doina Precup, S. Price, Tammy Riklin-Raviv, Syed M. S. Reza, Michael T. Ryan, Duygu Sarikaya, L. Schwartz, Hoo-Chang Shin, J. Shotton, Carlos Alberto Silva, N. Sousa, N. Subbanna, G. Székely, Thomas J. Taylor, O. Thomas, N. Tustison, Gözde B. Ünal, F. Vasseur, M. Wintermark, Dong Hye Ye, Liang Zhao, Binsheng Zhao, Darko Zikic, M. Prastawa, M. Reyes, K. V. Leemput   +67 more
semanticscholar   +1 more source

Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer

Molecular Oncology, EarlyView.
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte, Osheen Sharma, Laura Leuenberger, Emelie Wallin, Josefin Fernebro, Päivi Östling, Rebecka Bergström, Johan Lindberg, Ulrika Joneborg, Olli Kallioniemi, Brinton Seashore‐Ludlow   +10 more
wiley   +1 more source

Serum phosphohexose isomerase in cancer.II. As an index of tumor growth in metastatic carcinoma of the breast [PDF]

, 1954
Oscar Bodansky, Blossom Gershten, Charlotte Wilson   +2 more
openalex   +1 more source

Comprehensive omics‐based classification system in adult patients with B‐cell acute lymphoblastic leukemia

Molecular Oncology, EarlyView.
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song, Ting Liu, Qishan Hao, Qiuyun Fang, Xiaoyuan Gong, Yan Li, Zheng Tian, Hui Wei, Min Wang, Jianxiang Wang, Tao Cheng, Yingchang Mi   +11 more
wiley   +1 more source

Neoplastic Diseases. A Treatise on Tumors [PDF]

, 1941
James R. Ewing
openalex   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source